Bristol-Myers Squibb buy melinda
Start price
25.04.16
/
50%
€63.75
Target price
06.06.16
€66.75
Performance (%)
4.97%
End price
06.06.16
€66.92
Summary
This prediction ended on 06.06.16 with a price of €66.92. With a performance of 4.97%, the BUY prediction by melinda for Bristol-Myers Squibb closed with a slight gain. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Bristol-Myers Squibb | -10.081% | -10.081% | -32.071% | -20.715% |
| iShares Core DAX® | -1.370% | -3.231% | 11.661% | 16.545% |
| iShares Nasdaq 100 | 0.172% | -3.339% | 36.491% | 43.334% |
| iShares Nikkei 225® | -0.801% | -7.859% | 18.597% | 4.253% |
| iShares S&P 500 | -0.369% | -2.979% | 26.341% | 40.911% |
Comments by melinda for this prediction
In the thread Bristol-Myers Squibb diskutieren
Stier
(CercleFinance.com) - Bristol-Myers Squibb gab am Montag bekannt , dass die Food and Drug Administration den Status Opdivo therapeutischen Durchbruch gewährt hatte "(Durchbruch Therapie) bei der Behandlung von Krebs des Kopfes und des Halses.
Stopped prediction by melinda for Bristol-Myers Squibb
Bristol-Myers Squibb
Start price
Target price
Perf. (%)
€50.58
11.03.20
11.03.20
€55.00
04.11.21
04.11.21
1.07%
05.11.21
05.11.21
Bristol-Myers Squibb
Start price
Target price
Perf. (%)
€56.48
11.09.17
11.09.17
€64.94
15.02.18
15.02.18
9.10%
15.02.18
15.02.18
Bristol-Myers Squibb
Start price
Target price
Perf. (%)
€46.80
08.02.17
08.02.17
€51.41
01.03.17
01.03.17
10.02%
01.03.17
01.03.17